These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 19271940)

  • 21. Interferon-beta modifies the peripheral blood cell cytokine secretion in patients with multiple sclerosis.
    Mirandola SR; Hallal DE; Farias AS; Oliveira EC; Brandão CO; Ruocco HH; Damasceno BP; Santos LM
    Int Immunopharmacol; 2009 Jul; 9(7-8):824-30. PubMed ID: 19289181
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Blocking alpha4-integrins - A small molecule approach to treatment of multiple sclerosis.
    Davenport RJ; Munday JR
    J Neurol Sci; 2008 Nov; 274(1-2):27-30. PubMed ID: 18603264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N; Sorensen PS; Bendtzen K; Flachs EM
    Mult Scler; 2009 May; 15(5):601-5. PubMed ID: 19299439
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interleukin-25 inhibits interleukin-12 production and Th1 cell-driven inflammation in the gut.
    Caruso R; Sarra M; Stolfi C; Rizzo A; Fina D; Fantini MC; Pallone F; MacDonald TT; Monteleone G
    Gastroenterology; 2009 Jun; 136(7):2270-9. PubMed ID: 19505427
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differential IL-23 requirement for IL-22 and IL-17A production during innate immunity against Salmonella enterica serovar Enteritidis.
    Siegemund S; Schütze N; Schulz S; Wolk K; Nasilowska K; Straubinger RK; Sabat R; Alber G
    Int Immunol; 2009 May; 21(5):555-65. PubMed ID: 19297659
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E; Zivadinov R; Krasensky J; Dwyer MG; Novakova I; Dolezal O; Ticha V; Dusek L; Houzvickova E; Cox JL; Bergsland N; Hussein S; Svobodnik A; Seidl Z; Vaneckova M; Horakova D
    Mult Scler; 2009 Aug; 15(8):965-76. PubMed ID: 19465443
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Multimodality-evoked potential study of anti-aquaporin-4 antibody-positive and -negative multiple sclerosis patients.
    Watanabe A; Matsushita T; Doi H; Matsuoka T; Shigeto H; Isobe N; Kawano Y; Tobimatsu S; Kira J
    J Neurol Sci; 2009 Jun; 281(1-2):34-40. PubMed ID: 19339021
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Unbiased treatment effect estimates by modeling the disease process of multiple sclerosis.
    Healy BC; Hayden DL; Sampat MP; Bakshi R; Guttmann CR
    J Neurol Sci; 2009 Mar; 278(1-2):54-9. PubMed ID: 19121526
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Predicting and preventing the future: actively managing multiple sclerosis.
    Hutchinson M
    Pract Neurol; 2009 Jun; 9(3):133-43, discussion 144. PubMed ID: 19448055
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessing disability progression with the Multiple Sclerosis Functional Composite.
    Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
    Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study.
    Ebers GC; Reder AT; Traboulsee A; Li D; Langdon D; Goodin DS; Wolf C; Beckmann K; Konieczny A;
    Clin Ther; 2009 Aug; 31(8):1724-36. PubMed ID: 19808131
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vitamin D and multiple sclerosis: what are the guidelines for a reliable clinical trial?
    Féron F
    Expert Rev Neurother; 2010 Sep; 10(9):1375-8. PubMed ID: 20819008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
    Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
    Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus.
    Yao Y; Richman L; Higgs BW; Morehouse CA; de los Reyes M; Brohawn P; Zhang J; White B; Coyle AJ; Kiener PA; Jallal B
    Arthritis Rheum; 2009 Jun; 60(6):1785-96. PubMed ID: 19479852
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fampridine-SR for multiple sclerosis and spinal cord injury.
    Hayes KC
    Expert Rev Neurother; 2007 May; 7(5):453-61. PubMed ID: 17492896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anti-IL-33 antibody treatment inhibits airway inflammation in a murine model of allergic asthma.
    Liu X; Li M; Wu Y; Zhou Y; Zeng L; Huang T
    Biochem Biophys Res Commun; 2009 Aug; 386(1):181-5. PubMed ID: 19508862
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stress doses of hydrocortisone in high-risk patients undergoing cardiac surgery: effects on interleukin-6 to interleukin-10 ratio and early outcome.
    Weis F; Beiras-Fernandez A; Schelling G; Briegel J; Lang P; Hauer D; Kreth S; Kaufmann I; Lamm P; Kilger E
    Crit Care Med; 2009 May; 37(5):1685-90. PubMed ID: 19325469
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease.
    Brereton CF; Sutton CE; Lalor SJ; Lavelle EC; Mills KH
    J Immunol; 2009 Aug; 183(3):1715-23. PubMed ID: 19570828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.